Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States

CONCLUSIONS: Among immunocompromised adults, a 2-dose mRNA-1273 regimen was more effective in preventing medically-attended COVID-19 in any setting (inpatient and outpatient) than 2-dose BNT162b2. Results were similar for COVID-19 hospitalization, although statistical power was limited when using closed claims only.STUDY REGISTRATION: NCT05366322.PMID:36163093 | DOI:10.1016/j.vaccine.2022.09.025

Source: Vaccine - September 26, 2022 Category: Allergy & Immunology Authors: Katherine E Mues Brenna Kirk Deesha A Patel Alice Gelman L Scott Chavers Carla A Talarico Daina B Esposito David Martin James Mansi Xing Chen Nicolle M Gatto Nicolas Van de Velde Source Type: research